Reports Q3 revenue $14.46B, consensus $14.28B. “We delivered another quarter of strong commercial execution and significant pipeline progress,” said Robert Michael, chief executive officer, AbbVie (ABBV). “Based upon the momentum of AbbVie’s business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie small cell lung cancer treatment granted FDA orphan designation
- Notable companies reporting before tomorrow’s open
- M&A News: AbbVie (NYSE:ABBV) Will Acquire Aliada Therapeutics for $1.4B
- AbbVie to acquire Aliada Therapeutics for $1.4B in cash
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024